2 Scary Stocks
These stocks look overpriced.
Susan Dziubinski: Hi I’m Susan Dziubinski with Morningstar. U.S. stocks have posted frightening returns in 2022. After such gruesome performance, Morningstar estimates that U.S. stocks are about 18% undervalued.
But that doesn’t mean all stocks are screaming bargains—in fact, some still seem fiendishly overpriced to us. Today we’re looking at two overvalued stocks trading at scary prices.
2 Scary Stocks
These 1- and 2-star stocks are considered overpriced. Data as of Oct. 27, 2022.
The first scary stock is Marathon Oil (MRO). The independent exploration and production company has reshuffled its portfolio and is doubling down on U.S. shale. Like many shale companies, Marathon is prioritizing shareholder distributions rather than production growth. We don’t think the company has significant competitive advantages in the E&P space and, like most E&P firms, Marathon faces material ESG risk. We think the stock is expensive at today’s price and is worth just $18 per share.
The second spooky stock on our list is Dick’s Sporting Goods (DKS). While Dick’s is the largest independent sporting goods chain in the U.S., we think the company lacks an edge as sporting goods are sold through many channels. Intense competition from e-commerce platforms like Amazon.com AMZN, mass-market retailers like Walmart WMT, and specialty stores such as Nike NKE has reduced Dick’s customer traffic and eroded its operating margins. The stock looks expensive to us: We think shares are worth $78 each.
Thanks for tuning in. For more stock investing insights—spooky and otherwise—subscribe to Morningstar’s channel and visit Morningstar.com.
Morningstar director Dave Meats and analyst David Swartz contributed the research behind this segment.
Watch 2 Cheap Defensive Stocks for more from Susan Dziubinski.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.